Pilot Study: The Role of Macrophage Migration Inhibitory Factor (MIF) in Spinal Cord Injury

Completed

Conditions studied: Spinal Cord Injury

In brief

The purpose of the study is to investigate inflammatory and other substances that may be elevated in the blood and blood cells following spinal cord injury (SCI). These substances will be evaluated in samples from people who have had a spinal cord injury due to trauma (e.g. car accident or a fall) within the first week (acute) or at least one year ago (chronic). Specifically, the study will evaluate the presence and levels of a protein, macrophage migration inhibitory factor (MIF). MIF is released by cells and has a specific effect on the way cells behave, communicate and work together. In several other medical conditions, MIF is known to increase inflammation in the body. By comparing blood samples from individuals with spinal cord injury and uninjured (no spinal cord injury) individuals, the investigators will try to find out if MIF levels are increased in people with SCI. Investigators will also use these samples to measure other proteins that increase inflammation in the body and to see if the biological activities of MIF can be reduced in a test tube by adding other substances to the blood samples. It is hoped that this study of MIF and other proteins related to inflammation will help improve the treatment of SCI in the future. We hope to enroll a total of 312 subjects in this study (50 with acute spinal cord injury, 125 with chronic spinal cord injury, and 137 uninjured individuals).

Key facts

Study ID

NCT00919581

Run by

Northwell Health

People needed

149

Starts

2009-05-01

Expected to finish

2016-12-01

Last updated by the study team

2017-04-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• SCI Subject Inclusion Criteria: To be eligible for prospective enrollment, subjects are required to meet the following inclusion criteria:
• ≥18 years of age
• History SCI (acute or chronic): All American Spinal Injury Association (ASIA) classifications A-D and all levels.
• Healthy Control Subject Inclusion Criteria: To be eligible for prospective enrollment, healthy control subjects are required to meet the following inclusion criteria:
• ≥18 years of age
• The absence of any current or previous medical conditions
• To be eligible for prospective enrollment, SCI subjects are required to not meet the following exclusion criteria:
• < 18 years of age
• No known SCI
• Concurrent infection such as UTI
• Deep pressure sores
• cancer, chemotherapy or neutropenia
• autoimmune disease
• Healthy Control Subject Exclusion Criteria: To be eligible for prospective enrollment, healthy control subjects are required to not meet the following exclusion criteria:
• < 18 years of age
• Current or previous medical conditions

Where it is running

• Feinstein Institute for Medical Research, Northwell Health — Manhasset, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.